MT103-211

An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)

Participating sites in Europe

Please find below the participating site across Europe.

Participating Sites in France (29KB)

MT103-211

Participating Sites in Germany (34KB)

MT103-211

Participating Sites in Italy (31KB)

MT103-211

Participating Sites in Spain (30KB)

MT103-211

Participating Sites in the United Kingdom (29KB)

MT103-211

About us

The objective of the European LeukemiaNet is to integrate the leading leukemia trial groups (CML, AML, ALL, CLL, MDS, CMPD), their interdisciplinary partners (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a cooperative network for advancements in leukemia-related research and health care and cure.

MT103-211

About us

Lastest Posts

Links

Kontakt-Info